Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to $856000.0.

  • Wave Life Sciences' Depreciation & Amortization (CF) fell 970.46% to $856000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1383.29%. This contributed to the annual value of $3.9 million for FY2024, which is 2200.0% down from last year.
  • As of Q3 2025, Wave Life Sciences' Depreciation & Amortization (CF) stood at $856000.0, which was down 970.46% from $865000.0 recorded in Q2 2025.
  • Wave Life Sciences' Depreciation & Amortization (CF)'s 5-year high stood at $1.9 million during Q1 2021, with a 5-year trough of $856000.0 in Q3 2025.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $1.3 million (2023), whereas its average is $1.3 million.
  • Per our database at Business Quant, Wave Life Sciences' Depreciation & Amortization (CF) crashed by 446.3% in 2021 and then crashed by 2971.39% in 2023.
  • Over the past 5 years, Wave Life Sciences' Depreciation & Amortization (CF) (Quarter) stood at $1.8 million in 2021, then decreased by 14.37% to $1.5 million in 2022, then dropped by 29.71% to $1.1 million in 2023, then fell by 15.73% to $911000.0 in 2024, then fell by 6.04% to $856000.0 in 2025.
  • Its last three reported values are $856000.0 in Q3 2025, $865000.0 for Q2 2025, and $875000.0 during Q1 2025.